Diabetes · 2014 · 217 citations · 40 references
MedicineMolecular BiologyNephrologyGene ExpressionRenal PathophysiologyTranscriptional RegulationDiabetes MellitusDiabetes Mellitus BiochemistryDiabetic Kidney DiseaseDiabetic NephropathyPodocyte InjuryRenal DiseaseAdvanced Glycation End ProductsDiabetes Mellitus PathophysiologyDiabetic GlomerulosclerosisDiabetic Kidney Disease ProgressionProteinuria ReductionSirtuin 1 RegulationSirtuin RegulationTranscriptional Activation
Nuclear factor (NF)-κB and signal transducer and activator of transcription 3 (STAT3) play a critical role in diabetic nephropathy (DN). Sirtuin-1 (SIRT1) regulates transcriptional activation of target genes through protein deacetylation. Here, we determined the roles of Sirt1 and the effect of NF-κB (p65) and STAT3 acetylation in DN. We found that acetylation of p65 and STAT3 was increased in both mouse and human diabetic kidneys. In human podocytes, advanced glycation end products (AGEs) induced p65 and STAT3 acetylation and overexpression of acetylation-incompetent mutants of p65 and STAT3 abrogated AGE-induced expression of NF-κB and STAT3 target genes. Inhibition of AGE formation in db/db mice by pyridoxamine treatment attenuated proteinuria and podocyte injury, restored SIRT1 expression, and reduced p65 and STAT3 acetylation. Diabetic db/db mice with conditional deletion of SIRT1 in podocytes developed more proteinuria, kidney injury, and acetylation of p65 and STAT3 compared with db/db mice without SIRT1 deletion. Treatment of db/db mice with a bromodomain and extraterminal (BET)-specific bromodomain inhibitor (MS417) which blocks acetylation-mediated association of p65 and STAT3 with BET proteins, attenuated proteinuria, and kidney injury. Our findings strongly support a critical role for p65 and STAT3 acetylation in DN. Targeting protein acetylation could be a potential new therapy for DN.
40
Selective inhibition of BET bromodomains
P. Filippakopoulos, Jun Qi, S. Picaud et al. · Nature · 2010 · 4.3K citations · Full text
Stress-Dependent Regulation of FOXO Transcription Factors by the SIRT1 Deacetylase
Anne Brunet, Lora B. Sweeney, James Fitzhugh Sturgill et al. · Science · 2004 · 3.2K citations
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake Delmore, Ghayas C. Issa, Madeleine E. Lemieux et al. · Cell · 2011 · 2.8K citations · Full text
Negative Control of p53 by Sir2α Promotes Cell Survival under Stress
Jianyuan Luo, Anatoly Nikolaev, Shin‐ichiro Imai et al. · Cell · 2001 · 2.1K citations · Full text
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Johannes Zuber, Junwei Shi, Eric Wang et al. · Nature · 2011 · 1.9K citations